Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART19 + Ibrutinib in R/R CLL/SLL
NCT02640209Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Jan 2016
- Primary completion
- Oct 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tisagenlecleucel in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by University of Pennsylvania. Primary endpoint: Number of Adverse Events at 26 months. Started Jan 2016; status: terminated.
02
Drugs
tisagenlecleucel
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02640209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02640209.